Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
NCT ID NCT07632976
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an investigational biologic called EA5 in adults with antiphospholipid syndrome (APS) who have had two or more blood clots despite standard blood-thinning therapy. The study enrolls about 12 participants and gives EA5 by intravenous infusion followed by regular under-the-skin injections. The main goal is to check safety and tolerability, while also looking at whether EA5 can reduce clot events and affect immune markers related to APS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EA5 injection (a biologic given intravenously then subcutaneously)
What this could lead to
If safe and effective, EA5 could offer a new way to prevent blood clots in people with antiphospholipid syndrome who continue to clot despite standard therapy.
What could go wrong
This is a very early, small phase 1 study with only 12 participants, so results may not apply broadly. The main goal is safety, and the treatment may not reduce clots or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China